

CITATION REPORT

List of articles citing

Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction

DOI: 10.1111/j.1743-6109.2008.00935.x
Journal of Sexual Medicine, 2008, 5, 2160-9.

Source: <https://exaly.com/paper-pdf/43807442/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
70	Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. <i>European Urology</i> , 2008 , 54, 204-10	10.2	37
69	Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. <i>Current Medical Research and Opinion</i> , 2008 , 24, 3383-92	2.5	35
68	Tadalafil in the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 1315-30	2.9	57
67	Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. <i>Patient Preference and Adherence</i> , 2009 , 3, 105-11	2.4	9
66	Efficacy and safety of medium and long-term tadalafil use in spinal cord patients with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2009 , 6, 535-43	1.1	18
65	Safety, efficacy, and pharmacokinetic overview of low-dose daily administration of tadalafil. <i>Journal of Sexual Medicine</i> , 2009 , 6, 2039-48	1.1	51
64	The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2009 , 6, 2547-60	1.1	41
63	2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. <i>Journal of Sexual Medicine</i> , 2009 , 6, 2352-64; quiz 2365-6	1.1	31
62	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. <i>Der Urologe</i> , 2009 , 48, 1318, 1320-9		7
61	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, i-xiv	2.6	
60	A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition. <i>BJU International</i> , 2010 , 105, 1634-9	5.6	26
59	Long-Term Safety and Efficacy of Tadalafil 5mg Dosed Once Daily in Men with Erectile Dysfunction. <i>Yearbook of Urology</i> , 2009 , 2009, 192-193		
58	Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. <i>European Urology</i> , 2009 , 56, 727-35	10.2	62
57	Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. <i>European Urology</i> , 2010 , 58, 243-8	10.2	157
56	Reply from authors re: Konstatinos Hatzimouratidis. Can we cure erectile dysfunction? <i>Eur Urol</i> 2010;58:249-50. <i>European Urology</i> , 2010 , 58, 251-2	10.2	
55	Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 524-40	1.1	132
54	Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 3487-94	1.1	17

53	A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 159-71	4.4	23
52	Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. <i>Nature Reviews Urology</i> , 2010 , 7, 215-21	5.5	67
51	An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction. <i>Nature Reviews Urology</i> , 2010 , 7, 603-9	5.5	41
50	Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. <i>BJU International</i> , 2011 , 107, 1110-6	5.6	75
49	Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2011 , 8, 851-64	1.1	9
48	A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2617-24	1.1	20
47	Focus on phosphodiesterase inhibitors for the treatment of erectile dysfunction in older men. <i>Clinical Therapeutics</i> , 2011 , 33, 1590-608	3.5	10
46	Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. <i>European Urology</i> , 2011 , 60, 380-7	10.2	46
45	Endothelial apoptosis decrease following tadalafil administration in patients with arterial ED does not last after its discontinuation. <i>International Journal of Impotence Research</i> , 2011 , 23, 200-5	2.3	10
44	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1481-94	4	15
43	Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. <i>Drugs and Aging</i> , 2012 , 29, 771-81	4.7	8
42	Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. <i>Korean Journal of Urology</i> , 2012 , 53, 377-85		8
41	Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. <i>Urologia Internationalis</i> , 2013 , 91, 10-8	1.9	28
40	PDE5 inhibitors: considerations for preference and long-term adherence. <i>International Journal of Clinical Practice</i> , 2013 , 67, 768-80	2.9	73
39	A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. <i>Current Medical Research and Opinion</i> , 2013 , 29, 695-706	2.5	10
38	Efficacy and tolerability of udenafil in Turkish men with erectile dysfunction of psychogenic and organic aetiology: a randomized, double-blind, placebo-controlled study. <i>Andrology</i> , 2013 , 1, 549-55	4.2	8
37	SOP conservative (medical and mechanical) treatment of erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 130-71	1.1	117
36	[Drugs for sexual medicine]. <i>Progres En Urologie</i> , 2013 , 23, 1299-311	0.9	1

35	Erectile dysfunction. <i>Lancet, The</i> , 2013 , 381, 153-65	4.0	545
34	Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2013 , 10, 1592-602	1.1	26
33	Efficacy and safety of once-daily tadalafil in men with erectile dysfunction who reported no successful intercourse attempts at baseline. <i>Journal of Sexual Medicine</i> , 2013 , 10, 844-56	1.1	5
32	The effect of long-term oral tadalafil treatment on corpus cavernosum function in an experimental spinal cord transection rat model. <i>Spinal Cord</i> , 2013 , 51, 663-7	2.7	4
31	Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. <i>World Journal of Men's Health</i> , 2013 , 31, 83-102	6.8	22
30	Udenafil for the treatment of erectile dysfunction. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 341-54	2.9	16
29	Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. <i>International Journal of Impotence Research</i> , 2014 , 26, 223-9	2.3	12
28	The Efficacy and Safety of Tadalafil 5 mg Once Daily in the Treatment of Erectile Dysfunction After Robot-Assisted Laparoscopic Radical Prostatectomy: 1-Year Follow-up. <i>Korean Journal of Urology</i> , 2014 , 55, 112-9		15
27	Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. <i>European Urology</i> , 2014 , 65, 455-64	10.2	29
26	A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. <i>Journal of Sexual Medicine</i> , 2014 , 11, 187-96	1.1	51
25	Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis. <i>International Journal of Clinical Practice</i> , 2015 , 69, 436-43	2.9	7
24	Sexual Dysfunction in Men and Women. 2016 , 785-830		1
23	Drug therapy for erectile dysfunction. 2016 , 172-193		
22	A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2016 , 8, 100-17	3.2	8
21	Penile Low Intensity Shock Wave Treatment is Able to Shift PDE5i Nonresponders to Responders: A Double-Blind, Sham Controlled Study. <i>Journal of Urology</i> , 2016 , 195, 1550-1555	2.5	74
20	Sexual Dysfunction. 2016 , 2154-2162.e3		1
19	Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged \geq 5 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. <i>BJU International</i> , 2017 , 119, 793-803	5.6	19
18	Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. <i>International Journal of Impotence Research</i> , 2019 , 31, 195-203	2.3	24

17	Erectile Dysfunction. 2019 , 21-32		
16	Treatment persistence with a fixed-dose combination of tadalafil (5 mg) and tamsulosin (0.4 mg) and reasons for early discontinuation in patients with benign prostatic hyperplasia and erectile dysfunction. <i>Investigative and Clinical Urology</i> , 2020 , 61, 81-87	1.9	1
15	Sexual Dysfunction in Men and Women. 2011 , 778-816		2
14	Störungen der Erektion, Kohabitation und Ejakulation. 2009 , 283-324		
13	Erectile Dysfunction. 2010 , 163-179		
12	Disorders of Erection, Cohabitation, and Ejaculation. 2010 , 279-321		1
11	Erektile Dysfunktion (ED). 2010 , 749-764		
10	E. 2013 , 343-392		
9	PDE5 Inhibitors for the Treatment of Erectile Dysfunction in Patients with Hypertension. 2015 , 185-193		
8	Erectile Dysfunction. 2015 , 65-116		
7	Sex and Pharmacological Sexual Enhancement. 2017 , 387-411		
6	Evaluation of the long-term safety and effectiveness of tadalafil once daily in Chinese men with erectile dysfunction: interim results of a multicenter, randomized, open-label trial. <i>Asian Journal of Andrology</i> , 2018 , 20, 587-592	2.8	2
5	Erectile dysfunction in diabetes mellitus: A review. <i>Journal of Diabetology</i> , 2020 , 11, 1	0.8	1
4	Advances in sexual medicine: highlights from the 2007 winter meeting of the sexual medicine society of north america, december 6-9, 2007, chicago, IL. <i>Reviews in Urology</i> , 2008 , 10, 232-5	1	1
3	Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. <i>P and T</i> , 2013 , 38, 407-19	1.4	49
2	Tadalafil monotherapy in management of chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial. <i>World Journal of Urology</i> ,	4	1
1	Discontinuation Rates of Tadalafil Alone and in Combination with α -Blockers in the Treatment of Male Lower Urinary Tract Symptoms with or without Coexisting Erectile Dysfunction: A Systematic Review and Meta-Analysis. 2022 , 2022, 1-14		0